Divi's Laboratories share news and announcements
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Last close ₹8,950.00down ₹212.00 (2.31%)BSE ₹8,984.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹9,162.00.
52-week range of traded prices to 23 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,37,594 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 1 Aug 2026
- 81.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 14.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 1 Aug 2026
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 1 Aug 2026
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,20,26160.6% delivered
Divi's Laboratories shareholding disclosures
57 filed, newest first. Page 2 of 2.
Apr 2007
30 Apr · Disclosure
Two annual disclosure statements of employees and Directors of the Company for the year ended March 31, 2007 pursuant to the Regulation 13 of SEBI (Prohibition of Insider Trading) Regulations, 2002. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Apr · Disclosure
As per the SEBI (Prohibition of Insider Trading) Regulations, 2002, the following insider, who is a designated employee, has intimated the company on 26th April 2007, stating that he has gifted to his relative the following equity shares held by him in the Company: (1) Name of Designated Employee:- Mr. S Devendra Rao; No. of Shares Sold:- 276; Date of Execution:- 25.04.2007; Balance holding:- 216424 Apr · Disclosure
As per the SEBI (Prohibition of Insider Trading) Regulations, 2002, the following insider, who is a designated employee, has intimated the company on 20th April 2007, stating that he has sold the equity shares held by him in the Company: (1) Name of Designated Employee:- Mr. B Vara Prasad; No. of Shares Sold:- 670; Date of Execution:- 17.04.2007; Balance holding:- 2
Mar 2007
30 Mar · Disclosure
As per the SEBI (Prohibition of Insider Trading) Regulations 2002, the insiders (as per list enclosed), who are designated employees, have intimated the Company, stating that their holdings have changed consequent to the allotment of shares under Employee Stock Option Scheme 2006 of the company. The details of the the list shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Mar · Disclosure
As per the SEBI (Prohibition of Insider Trading) Regulations, 2002, the following insider, who is designated employee, has intimated the company on 1st March 2007, stating that he has acquired the equity shares of the Company : (1) Name of Designated Employee :- Mr. P Srinivas Rao; No. of Shares acquired :- 4500; Mode of Acquisition :- Market; Market Price :- Rs.2990; Total holding - 18991
Feb 2007
6 Feb · Disclosure
As per the SEBI (Prohibition of Insider Trading) Regulation, 2002, the following insider, who is designated employee, have intimated the company on 3rd February 2007, stating that they he have acquired on 31st January 2007 the shares of the Company : (1) Name of Designated Employee :- Mr. S. Rama Krishna; No. of Shares acquired :- 1000; Mode of Acquisition :- Market; Market Price :- Rs. 3170; Total holding - 5501
Jan 2007
4 Jan · Disclosure
The Oppenheimer Funds Inc. A/C Oppenheimer Developing Markets Fund, which holds more than 5% shares in the company, has sold 152312 No. of shares amounting to 1.19% of total shareholding, which has resulted in shareholding falling below 5%. As per Regulation 7(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and in terms of regulations 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992, company has to disclose purchase or sale aggregating 2% or more of total share capital of the company even if such change results in shareholding falling below 5%. In this case, though the change does not exceed 2% of total shareholding, we are intimating the same for your information and records. Name of Shareholder - Oppenheimer Funds Inc. A/C Oppenheimer Developing Markets Fund; No & % of shares Sold - 152312 (1.19%); Shareholding before Sale % - 641907 (5.01%); Shareholding after Sale % - 489595 (3.82%)